Can I Take Resveratrol with Osphena (Ospemifene)? A Women's Health Guide

What Is Osphena and Who Takes It?

Osphena is the brand name for ospemifene, a selective estrogen receptor modulator (SERM) approved by the FDA in 2013 for moderate-to-severe dyspareunia caused by vulvovaginal atrophy (VVA) of menopause, now more commonly called genitourinary syndrome of menopause (GSM). Unlike topical estrogen creams or rings, you take ospemifene as a 60 mg oral tablet once daily with the largest meal of the day, which improves absorption by roughly 2.7-fold compared with a fasted state.

What Makes Ospemifene Different from Other GSM Treatments

SERMs bind estrogen receptors but act differently in different tissues. Ospemifene acts as an estrogen agonist in vaginal epithelium, improving cell maturation and lubrication, while acting as a neutral agent or weak antagonist in breast tissue. This tissue selectivity is why it is offered as a non-hormonal option for women who cannot or prefer not to use topical estrogen.

The 2022 Menopause Society (NAMS) position statement on GSM lists ospemifene as an effective systemic oral option for dyspareunia when vaginal therapies are not appropriate or desired. A Phase 3 trial published in Menopause showed ospemifene significantly improved the most bothersome symptom score versus placebo at 12 weeks, with a mean change of 1.57 versus 1.02 in controls.

Life-Stage Context

Ospemifene is indicated specifically for postmenopausal women. That includes natural menopause (12 consecutive months without a period), surgical menopause following bilateral oophorectomy at any age, and premature ovarian insufficiency (POI) after age-appropriate evaluation. Women in perimenopause, who still have variable estrogen production, are generally not candidates because the drug's tissue effects have not been evaluated in the presence of fluctuating endogenous estrogen.

What Is Resveratrol and Why Are Postmenopausal Women Taking It?

Resveratrol is a polyphenol found in grape skins, red wine, and certain berries. It is sold widely as a longevity and antioxidant supplement, often marketed to women over 40 as a way to support cardiovascular health, metabolic function, and even bone density after menopause. Doses in consumer supplements typically range from 100 mg to 1,000 mg per day, though some "high-dose" protocols marketed online go higher.

The enthusiasm is understandable. A 2020 randomized controlled trial published in Menopause found that 150 mg/day of resveratrol over 14 weeks improved cerebrovascular responsiveness and cognitive performance in postmenopausal women compared with placebo. A separate 2017 trial in the same journal showed 75 mg twice daily of resveratrol for 12 weeks reduced vasomotor symptoms and improved quality-of-life scores in postmenopausal women, though effect sizes were modest.

Resveratrol's Estrogenic Activity: The Core Concern

Resveratrol binds estrogen receptors ERα and ERβ. Its affinity is far lower than estradiol, but the binding is real. In cell and animal studies, resveratrol acts as a selective estrogen receptor modulator in its own right, with tissue-specific agonist and antagonist effects that overlap mechanistically with drugs like tamoxifen and ospemifene. This is not a theoretical concern extrapolated from distant chemistry. The same receptor pathways that ospemifene activates in vaginal epithelium and potentially in endometrial tissue are pathways resveratrol also touches.

The Two Types of Interaction You Need to Know About

When a supplement and a prescription drug interact, the mechanism matters because it determines how serious the interaction is, whether timing the doses apart helps, and what monitoring is needed. With resveratrol and ospemifene, there are two distinct interaction mechanisms running in parallel.

Pharmacokinetic Interaction: CYP Enzymes

Ospemifene is metabolized primarily by CYP3A4 and CYP2C9, with minor contributions from CYP2C19. Resveratrol is a known inhibitor of both CYP3A4 and CYP2C9 in vitro. A 2010 study published in Drug Metabolism and Disposition found that resveratrol at doses achievable with supplements inhibited CYP2C9 activity by up to 55% in human liver microsomes. A separate analysis confirmed CYP3A4 inhibition by resveratrol in human hepatic systems.

What does this mean for you? If resveratrol slows the enzymes that break down ospemifene, ospemifene blood levels could rise above the intended therapeutic range. The ospemifene prescribing information already flags that co-administration with fluconazole, a strong CYP2C9 and moderate CYP3A4 inhibitor, increased ospemifene AUC by 2.7-fold. Resveratrol is a weaker inhibitor than fluconazole, but the direction of effect is the same: more ospemifene exposure than intended.

Higher ospemifene exposure is not confirmed safe. The drug's endometrial safety data, which showed a low rate of endometrial hyperplasia at the approved 60 mg dose, were generated without accounting for co-administered CYP inhibitors.

Can dose separation help? Spacing resveratrol and ospemifene by several hours does not reliably solve a CYP inhibition interaction. Enzyme inhibition is not a simple competition at the absorption site. It reflects changes in enzyme activity that persist for hours after the inhibitor is cleared from the gut, meaning taking your supplement in the morning and your tablet at dinner does not eliminate the pharmacokinetic risk.

Pharmacodynamic Interaction: Additive Estrogen-Receptor Stimulation

Even setting aside metabolism, resveratrol's ER-binding activity layered on top of ospemifene's ER agonism creates additive receptor stimulation. Ospemifene already carries an FDA boxed warning for endometrial cancer risk in women with an intact uterus, specifying that unopposed estrogen-agonist activity in the endometrium increases cancer risk and that endometrial monitoring may be needed in symptomatic patients.

Resveratrol has been shown in endometrial cell lines to stimulate proliferation through ERα at higher concentrations, though the clinical translation of cell-line data is always uncertain. No human trial has examined endometrial thickness or hyperplasia rates in women taking the resveratrol-plus-ospemifene combination. The evidence gap here is real and clinically meaningful.

A practical framework for thinking about this dual interaction:

| Interaction Layer | Mechanism | Can Dose Timing Fix It? | Clinical Risk Level | |---|---|---|---| | CYP3A4/2C9 inhibition | Resveratrol slows ospemifene breakdown, raising drug levels | No | Moderate (uncertain) | | ER additive agonism | Both compounds stimulate estrogen receptors in uterine tissue | No | Unknown (no human data) | | Breast tissue | Ospemifene is neutral/weak antagonist; resveratrol is weak agonist | Not applicable | Likely low but unquantified |

What the Evidence Actually Shows (And What It Doesn't)

Honesty about the evidence matters here. No published randomized controlled trial has enrolled postmenopausal women on ospemifene and then added resveratrol to measure outcomes. Every claim in this article about the combination is built from:

1. Ospemifene pharmacokinetics and the known sensitivity of its clearance to CYP inhibitors (FDA label data, Phase 1 interaction studies).
2. Resveratrol's measured enzyme inhibition in human liver systems (in vitro pharmacology).
3. Resveratrol's documented ER binding and ER-mediated cell activity (receptor pharmacology).
4. Extrapolation from the ospemifene-fluconazole interaction as a mechanistic analog.

This is not a small footnote. Women have been historically under-represented in pharmacokinetic drug-drug interaction studies, and supplement-drug interaction data for women going through menopause is especially thin. The NIH Office of Research on Women's Health has repeatedly flagged this as a gap, particularly for drugs used predominantly in female populations where CYP enzyme activity may itself shift with declining estrogen.

The Menopause Society's clinical guidance does not currently address resveratrol co-administration with SERMs, reflecting the absence of trial data rather than a reassurance of safety.

Sex-Specific Physiology: How Menopause Changes the Picture

Postmenopause changes drug metabolism in ways that matter for this combination.

CYP Enzyme Activity After Menopause

Estrogen modulates CYP3A4 expression. After menopause, with endogenous estrogen falling, CYP3A4 activity may shift, though the direction and magnitude vary by individual. Women also show baseline differences from men in CYP2C9 activity. The FDA label for ospemifene was developed in predominantly postmenopausal female study populations, so the approved dose reflects that context. Adding a CYP inhibitor on top of a population that already has different baseline CYP activity from the male default used in many early pharmacokinetic trials is a compounding unknown.

Surgical Menopause

Women who undergo bilateral oophorectomy, sometimes as young as their 30s for conditions like endometriosis, ovarian cancer risk reduction (BRCA variants), or severe PCOS-related complications, experience abrupt estrogen loss rather than gradual decline. GSM symptoms can appear quickly and severely in surgical menopause. If you are in this group and are prescribed ospemifene, discuss resveratrol with your clinician. The abrupt hormonal shift may alter your CYP baseline differently from natural menopause.

PCOS and Earlier Life Stages

Resveratrol has been studied separately as a treatment for polycystic ovary syndrome (PCOS) in premenopausal women. A 2016 trial in the Journal of Clinical Endocrinology and Metabolism found 1,500 mg/day of resveratrol for three months significantly reduced testosterone and DHEAS levels in women with PCOS. Ospemifene is not indicated in this population. However, if you have a history of PCOS and are now postmenopausal and on ospemifene, your prescriber should know you are considering resveratrol, because the hormonal context of your history is relevant.

Pregnancy, Lactation, and Contraception

Ospemifene is contraindicated in pregnancy. This must be stated plainly.

The FDA label assigns ospemifene Pregnancy Category X, meaning animal reproduction studies have shown fetal abnormalities and the risks outweigh any potential benefit in a pregnant woman. Animal data showed dose-dependent fetal loss and developmental toxicity at doses below the human therapeutic dose. There are no adequate and well-controlled studies in pregnant humans, and none should be conducted given the animal signal.

Ospemifene is indicated only for postmenopausal women, and most users will be well past reproductive years. However, surgical menopause can occur before natural menopause, and some women in their 40s with POI may still have theoretical pregnancy potential if the diagnosis is not complete ovarian failure. If there is any doubt about menopausal status, a pregnancy test and reliable contraception should be confirmed before starting ospemifene.

Lactation: Ospemifene should not be used by breastfeeding women. It is not known whether ospemifene is excreted in human breast milk, but given the drug's estrogenic activity and its lipophilicity, transfer is plausible. Because GSM is a postmenopausal condition, this is rarely a clinical scenario, but women with surgical menopause postpartum represent an edge case where the question could arise.

Resveratrol in pregnancy: Resveratrol has no established safe dose in human pregnancy. Animal studies have shown dose-dependent effects on fetal development, including disruption of placental function at high doses. Resveratrol should be avoided in pregnancy and during breastfeeding. A 2016 primate study published in FASEB Journal showed high-dose resveratrol supplementation in pregnant macaques impaired fetal pancreatic development, a finding that shifted clinical guidance toward caution.

Who This Combination Is Right For and Who Should Avoid It

You may be able to continue resveratrol with careful monitoring if:

• You have discussed both agents with your gynecologist or menopause specialist.
• You are taking low-dose resveratrol (under 150 mg/day), which represents weaker CYP inhibition.
• You have a uterus, are on ospemifene, and agree to periodic endometrial monitoring (e.g., annual transvaginal ultrasound to check endometrial thickness).
• You have no personal or first-degree family history of estrogen-sensitive endometrial cancer.
• Your provider has reviewed your full medication list for additive CYP inhibition from other sources (azole antifungals, certain SSRIs, grapefruit).

You should not combine resveratrol and ospemifene without medical review if:

• You have an intact uterus and are not doing any endometrial surveillance.
• You are already taking other CYP3A4 or CYP2C9 inhibitors, because the cumulative inhibition could be additive.
• You have a personal history of endometrial hyperplasia or endometrial cancer.
• You are taking ospemifene for dyspareunia related to breast cancer treatment (aromatase inhibitor-induced GSM) and have an estrogen-sensitive tumor, because resveratrol's ER activity is poorly characterized in this setting.
• You are pregnant or trying to conceive (ospemifene is contraindicated outright).

A Note for Women with Breast Cancer History

Ospemifene is sometimes considered in women with a history of hormone-receptor-negative breast cancer who have severe GSM symptoms and cannot use vaginal estrogen. The oncology and gynecology literature remains cautious here. If you are in this group, resveratrol's ER activity should be specifically evaluated by your oncologist, not just your OB-GYN, before you add it.

What to Do If You Are Already Taking Both

If you are already taking resveratrol and ospemifene together and have not had this conversation with your prescriber, here are the concrete next steps:

1. Do not stop ospemifene abruptly without talking to your provider. GSM symptoms return quickly when the drug is stopped, and unplanned discontinuation can leave you without effective symptom control.
2. Book a medication review appointment. Bring the exact product, dose, and how long you have been combining them.
3. If you have an intact uterus and have not had an endometrial ultrasound in the past 12 months, ask whether one is warranted given the potential additive estrogenic exposure.
4. Report any new symptoms: unexpected vaginal spotting or bleeding is the most important red flag for endometrial stimulation and should prompt same-week evaluation, not watchful waiting.
5. Consider whether the resveratrol goal can be met another way. Cardiovascular and cognitive benefits in postmenopausal women may overlap with those offered by physical activity, dietary pattern changes, or other supplements without ER activity.

Monitoring Parameters if Your Clinician Approves the Combination

If your provider reviews your case and decides the combination is acceptable for you, ask about the following monitoring plan:

• Endometrial thickness: Transvaginal ultrasound at baseline and then at 6 to 12 months. An endometrial stripe of 5 mm or less on TVUS is considered within normal limits for postmenopausal women not on hormones; thresholds may need adjustment if additive estrogenic stimulation is suspected.
• Symptom diary: Track any breakthrough bleeding, spotting, pelvic pain, or new breast changes.
• CYP inhibitor audit: Have your pharmacist or provider check every prescription drug, OTC product, and supplement you take for CYP3A4/2C9 inhibitory activity so the cumulative burden is understood.
• Ospemifene efficacy check: If ospemifene side effects increase (hot flushes, vaginal discharge, muscle spasm), that may signal higher-than-expected drug levels from enzyme inhibition.

Talking to Your Provider: What to Say

Many women feel uncertain about bringing up supplements in a clinical visit, especially when the appointment is focused on a prescription medication. You do not need to apologize for taking resveratrol or frame it as doing something wrong. A direct, factual approach works best:

"I've been taking [dose] mg of resveratrol daily for [duration]. I know it may affect the same enzymes that break down ospemifene, and I've read it also has some estrogen-receptor activity. Can we talk about whether I should continue it, and whether I need any additional monitoring?"

That framing gives your clinician the information they need to have a productive conversation with you.

Rachel Goldberg, MD, WomanRx editorial board member and menopause specialist, notes: "The resveratrol-ospemifene combination is one I see come up regularly now that resveratrol is heavily marketed to women in their 50s and 60s. My concern is not that it is definitively dangerous, but that we have no human data on the endometrial implications of adding a weak ER ligand on top of a SERM in a woman with an intact uterus. Until we do, I want to know about it, and I want to monitor those patients more carefully."

Alternatives to Resveratrol for Common Postmenopausal Goals

If your primary motivation for resveratrol is cardiovascular health, bone support, or cognitive function during menopause, there are supplement or lifestyle options without ER activity to consider:

• Cardiovascular health: Omega-3 fatty acids (EPA/DHA at 1 to 4 g/day) have Level A evidence from AHA for triglyceride lowering without receptor-mediated hormonal activity.
• Bone health: Calcium (1,200 mg/day from food and supplement combined) plus vitamin D3 (1,500 to 2,000 IU/day) is supported by ACOG for postmenopausal women at risk for osteoporosis.
• Cognitive support: The MIND diet pattern has been associated with slower cognitive decline in women and does not require supplementation.

None of these alternatives carry the CYP inhibition or ER activity concerns associated with resveratrol at typical supplement doses.